HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of small cell lung cancer patients.

Abstract
Small cell lung cancers, comprising approximately 20% of lung cancers, are rapidly growing and disseminating carcinomas which are initially chemosensitive but acquire drug resistance during the course of disease. Thus, outcome is poor with median survival of 10-16 months for patients with limited and 7-11 months for patients with extensive disease. Polychemotherapy with established drugs (platins, etoposide, anthracyclines, cyclophosphamide, ifosfamide and Vinca alkaloids) plays the major role in the treatment of this disease and results in overall response rates between 80%-95% for limited disease and 60%-80% for extensive disease. Dose-intensified chemotherapy and high-dose chemotherapy with peripheral blood progenitor cell support were tested in several trials but their exact impact on outcome remains to be determined. New drugs including the taxanes (paclitaxel, docetaxel), the topoisomerase I inhibitors (topotecan, irinotecan), vinorelbine and gemcitabine are currently evaluated in clinical trials. In limited disease, thoracic radiotherapy improves survival and prophylactic cranial irradiation should be administered to those with a reasonable chance of cure.
AuthorsS Zöchbauer-Müller, R Pirker, H Huber
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 10 Suppl 6 Pg. 83-91 ( 1999) ISSN: 0923-7534 [Print] England
PMID10676558 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
Topics
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Marrow Transplantation
  • Carcinoma, Small Cell (drug therapy, radiotherapy, surgery, therapy)
  • Combined Modality Therapy
  • Hematopoietic Stem Cells
  • Humans
  • Lung Neoplasms (drug therapy, radiotherapy, surgery, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: